

TABLE OF CONTENTS

ILLUSTRATIONS IN THIS BOOK	iv
PSAP-VII EDITORIAL BOARD.....	v
WELCOME.....	vi
FACULTY POTENTIAL COI DISCLOSURE.....	vii
ROLE OF ACCP.....	vii
ROLE OF BPS.....	vii
CPE AND PROGRAM INSTRUCTIONS.....	viii
POSTTEST INSTRUCTIONS.....	viii

Pediatrics I	1
Pediatrics I Panel	3
Pediatrics I Subscriber Evaluation	5

PHARMACOGENOMICS AND PEDIATRIC PHARMACOTHERAPY

By Mary Jayne Kennedy, Pharm.D., DACBP

Introduction.....	7
Basic Principles of Genetics.....	8
Genes and Gene Expression.....	8
Variation in the Human Genome.....	8
Genomic Variation and Drug Response.....	9
Pharmacokinetics.....	9
Pharmacodynamics.....	11
Identifying Gene-Response Associations.....	12
Candidate Gene Studies.....	12
Genome-Wide Association Studies.....	14
Examples of Gene-Response Associations.....	14
Relevant to Pediatrics.....	14
Thiopurine Methyltransferase and 6-Mercaptopurine.....	14
Cysteinyl Leukotrienes and Leukotriene Modifiers.....	15
Maternal CYP2D6 Genotype and Opioid Exposure in Breastfeeding Infants.....	15
Incorporating Pharmacogenomics into Pediatric Pharmacotherapy.....	16
Factors Influencing the Clinical Utility of Pharmacogenomics Testing.....	16
Challenges in the Clinical Application of Pharmacogenomics.....	16
Developmental Considerations.....	17
Identifying Appropriate Indications for Pharmacogenomics Testing.....	18
Special Pediatric Considerations.....	18
Ethical Concerns.....	19
Role of the Pharmacist.....	20
Conclusion.....	21
Annotated Bibliography.....	21
Self-Assessment Questions.....	25

SICKLE CELL DISEASE

By Tracy Hagemann, Pharm.D., FCCP

Introduction.....	29
Epidemiology.....	29
Incidence.....	30

Pathophysiology.....	30
Clinical Presentation and Diagnosis.....	30
Neonatal Screening.....	30
Signs and Symptoms.....	30
Health Supervision Monitoring.....	31
Growth and Development.....	31
Morbidity and Mortality.....	31
Quality Patient Care.....	31
Family and Patient Education.....	31
Preventive Pharmacotherapy.....	31
Acute Complication Management.....	35
Management of Crises.....	37
Hematopoietic Stem Cell Transplantation.....	38
The Role of the Pharmacist.....	39
Annotated Bibliography.....	39
Self-Assessment Questions.....	45

POISONING AND ENVENOMATION

By Mark R. Haase, Pharm.D., FCCP, BCPS

Introduction.....	49
National Poison Data System.....	49
Poison Center Role in Data Collection.....	50
Trends in Pediatric Exposures.....	50
Clinical Evaluation of the Poisoned Child.....	50
Triage.....	50
Supportive Care.....	50
History and Physical Examination.....	51
Laboratory Evaluation.....	51
Decontamination.....	52
Syrup of Ipecac.....	52
Gastric Lavage.....	52
Activated Charcoal.....	52
Whole Bowel Irrigation.....	54
Poisoning with Selected Agents.....	54
Acetaminophen.....	54
Ethylene Glycol and Methanol.....	55
Nonprescription Drugs.....	57
Crotaline Envenomation.....	58
Poison Prevention Education.....	59
Conclusion.....	59
Annotated Bibliography.....	59
Self-Assessment Questions.....	63

Pediatrics II	67
----------------------------	----

Pediatrics II Panel	69
----------------------------------	----

Subscriber Evaluation Pediatrics II	71
--	----

LEGISLATION, REGULATIONS, AND GUIDANCES AFFECTING PEDIATRIC PHARMACOTHERAPY

By Gilbert J. Burckart, Pharm.D., FCCP

Introduction.....	73
Historical Background.....	73

Important Regulations Related to Pediatric Drug Therapy	75
National Research Act	75
Pediatric Research Equity Act	75
Best Pharmaceuticals for Children Act	75
The Orphan Drug Act	77
European Medicines Agency	77
Guidances Related to Pediatric Drug Development	77
International Conference on Harmonization	
E11: Clinical Investigation of Medicinal Products	
in the Pediatric Population	77
FDA Guidance for Industry	78
Important Concepts	79
Extrapolation and Interpolation	79
Pharmacokinetics and Pharmacodynamics	79
Pediatric Drug Safety	79
The Future of Pediatric Drug Development	79
Annotated Bibliography	81
Self-Assessment Questions	85

EXTEMPORANEOUS FORMULATIONS

By Vinita B. Pai, Pharm.D., M.S.;
and Milap C. Nahata, Pharm.D., M.S.

Introduction	89
Need for Extemporaneous Formulations	90
Options for Providing Formulations	91
Essential Components for Preparing	
Extemporaneous Formulations	92
Quality Suspensions	92
Suspending Agents	93
Preparation of Extemporaneous Formulations	93
Stability and Sterility Testing of Formulations	94
Stability	94
Sterility	95
Efficacy and Safety of Extemporaneous Formulations	96
Role of the Pharmacist	97
Annotated Bibliography	97
Self-Assessment Questions	101

GASTROESOPHAGEAL REFLUX DISEASE

By Kalen B. Porter, Pharm.D., BCPS, AE-C

Introduction	105
Definitions	105
Epidemiology	106
Clinical Practice Guidelines	106
Gastroesophageal Reflux	106
Pathophysiology	106
Clinical Presentation	108
Diagnosis	108
Treatment Goals	108
Quality Patient Care	108
Gastroesophageal Reflux Disease	109
Pathophysiology	109
Clinical Presentation	109
Diagnosis	109
Treatment	110
Quality of Life	117
The Role of the Pharmacist	117
Annotated Bibliography	118
Self-Assessment Questions	123

PARENTERAL NUTRITION IN THE NEONATE

By Claudia Kamper, Pharm.D., BCNSP.

Introduction	127
Growth	128
Indication for Parenteral Nutrition	128
Parenteral Nutrient Requirements	130
Fluid and Sodium	130
Macronutrients	130
Micronutrients	133
Complications of PN	135
Hyperglycemia	135
Metabolic Bone Disease	136
Parenteral Nutrition–Associated Cholestasis	136
CVC-Related Infections	136
Special Challenges	137
Cardiac Surgery	137
Extracorporeal Membrane Oxygenation	137
Patient Safety Issues	138
Role of the Pharmacist	138
Annotated Bibliography	139
Self-Assessment Questions	143

Pediatrics III 147

Pediatrics III Panel 149

Subscriber Evaluation Pediatrics III 151

HYPERGLYCEMIA OF CRITICAL ILLNESS AND PULMONARY ARTERIAL HYPERTENSION

By David S. Hoff, Pharm.D., FCCP

Introduction	153
Hyperglycemia of Critical Illness	153
Pediatric Subpopulations	155
Treatment Goals	157
Quality Patient Care	157
Conclusion	160
Pediatric PAH	160
Differences Between Children and Adults	161
Populations with PAH	161
Pharmacotherapy Treatment Goals	162
Conclusion	166
Annotated Bibliography	166
Self-Assessment Questions	171

MANAGEMENT OF THE POSTOPERATIVE PATIENT AFTER CONGENITAL HEART DISEASE REPAIR

By Elizabeth Anne Farrington, Pharm.D., FCCP,
FCCM, BCPS

Introduction	175
Perioperative Issues	176
Inflammatory Response	176
Modified Ultrafiltration	176
Hypothermia	178
Postoperative Complications	178
Coagulopathy/Hemorrhage	178
Low Cardiac Output Syndrome	179

Fluid Overload	183
Hyperglycemia	184
Pulmonary Hypertension	184
Postoperative Dysrhythmias	185
Role of the Pharmacist	186
Annotated Bibliography	186
Self-Assessment Questions	189

ACUTE AND CHRONIC KIDNEY DISEASE..

By Christopher L. Shaffer, Pharm.D., BCPS; and

Carisa J. Schweitzer Masek, Pharm.D.

Introduction	193
Epidemiology	193
Pathophysiology	194
Acute Kidney Injury	194
Congenital, Genetic, and Developmental	
Kidney Disease	196
Screening and Diagnosis	196
Acute Kidney Injury	196
Chronic Kidney Disease	198
Pharmacotherapy	199
Antibiotics	199
Anti-inflammatory Agents	201
Fluid and Electrolyte Homeostasis	202
Peritoneal Dialysis and Hemodialysis	202
Growth and Nutrition	203
Anemia	204
Hypertension	204
The Role of the Pharmacist	204
Annotated Bibliography	205
Self-Assessment Questions	207
Reference Values for Common Laboratory Tests ^a	212